Phase II study of weekly gemcitabine in patients with metastatic breast cancer relapsing or failing both an anthracycline and a taxane
A phase II study was performed to investigate the efficacy and tolerability of gemcitabine as third-line chemotherapy for patients with metastatic breast cancer, previously treated with both an anthracycline- and taxane-containing regimen. Twenty-three patients were treated with gemcitabine 1200 mg/...
Gespeichert in:
| Veröffentlicht in: | Breast cancer research and treatment 2001-03, Vol.66 (1), p.83-87 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 87 |
|---|---|
| container_issue | 1 |
| container_start_page | 83 |
| container_title | Breast cancer research and treatment |
| container_volume | 66 |
| creator | SMORENBURG, C. H BONTENBAL, M SEYNAEVE, C VAN ZUYLEN, C DE HEUS, G VERWEIJ, J DE WIT, R |
| description | A phase II study was performed to investigate the efficacy and tolerability of gemcitabine as third-line chemotherapy for patients with metastatic breast cancer, previously treated with both an anthracycline- and taxane-containing regimen. Twenty-three patients were treated with gemcitabine 1200 mg/m2 in a 30-min infusion on day 1, 8 and 15 of a 28 day cycle. Seventy-four percent of the patients had visceral metastases. No complete or partial responses were observed. Six patients (26%) had stable disease with a median duration of 4.0 months. The median time to progression was 1.9 months and the median survival time was 7.8 months. Neutropenia grade 3 and 4 was observed in four patients (18%). Non-hematological toxicity grade 3 included nausea and vomiting in 14%, skin toxicity in 9% and elevation of transaminases in 23% of the patients. Gemcitabine is ineffective as third-line single agent therapy in patients failing anthracycline and taxane treatment for metastatic breast cancer. |
| doi_str_mv | 10.1023/A:1010679127390 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_212465691</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>390309381</sourcerecordid><originalsourceid>FETCH-LOGICAL-c348t-4db95f92f1bc6f1466a8e5f2801f5654cc5904ea3fadbdc3f6fffcfc9b6be61d3</originalsourceid><addsrcrecordid>eNpVkEGLFDEQhYMo7rh69iZBz-2mOul0x9uwrDqwoAc9N5V0ZSdrT3pMMqzzB_zdZthBEQrqUXzvFTzGXoN4D6KVV-sPIEDo3kDbSyOesBV0vWz6FvqnbCVA940ehL5gL3K-F0KYXpjn7AJA6kGBWrHfX7eYiW82PJfDdOSL5w9EP-Yjv6OdCwVtiMRD5HssgWLJ_CGULd9RwVzqyXGbqEruMDpKPNGM-xziHV8S9xjmk7RLtWCsU7YJ3dHNp1CME0de8BdGesmeeZwzvTrvS_b9482368_N7ZdPm-v1beOkGkqjJms6b1oP1mkPSmscqPPtIMB3ulPOdUYoQulxspOTXnvvnXfGaksaJnnJ3j7m7tPy80C5jPfLIcX6cmyhVbrTBip09Qi5tOScyI_7FHaYjiOI8VT7uB7_q7063pxjD3ZH0z_-3HMF3p0BzA5nn2pbIf_ljJa9AvkHK9SMQw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>212465691</pqid></control><display><type>article</type><title>Phase II study of weekly gemcitabine in patients with metastatic breast cancer relapsing or failing both an anthracycline and a taxane</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>SMORENBURG, C. H ; BONTENBAL, M ; SEYNAEVE, C ; VAN ZUYLEN, C ; DE HEUS, G ; VERWEIJ, J ; DE WIT, R</creator><creatorcontrib>SMORENBURG, C. H ; BONTENBAL, M ; SEYNAEVE, C ; VAN ZUYLEN, C ; DE HEUS, G ; VERWEIJ, J ; DE WIT, R</creatorcontrib><description>A phase II study was performed to investigate the efficacy and tolerability of gemcitabine as third-line chemotherapy for patients with metastatic breast cancer, previously treated with both an anthracycline- and taxane-containing regimen. Twenty-three patients were treated with gemcitabine 1200 mg/m2 in a 30-min infusion on day 1, 8 and 15 of a 28 day cycle. Seventy-four percent of the patients had visceral metastases. No complete or partial responses were observed. Six patients (26%) had stable disease with a median duration of 4.0 months. The median time to progression was 1.9 months and the median survival time was 7.8 months. Neutropenia grade 3 and 4 was observed in four patients (18%). Non-hematological toxicity grade 3 included nausea and vomiting in 14%, skin toxicity in 9% and elevation of transaminases in 23% of the patients. Gemcitabine is ineffective as third-line single agent therapy in patients failing anthracycline and taxane treatment for metastatic breast cancer.</description><identifier>ISSN: 0167-6806</identifier><identifier>EISSN: 1573-7217</identifier><identifier>DOI: 10.1023/A:1010679127390</identifier><identifier>PMID: 11368414</identifier><identifier>CODEN: BCTRD6</identifier><language>eng</language><publisher>Dordrecht: Springer</publisher><subject>Adult ; Aged ; Antibiotics, Antineoplastic - therapeutic use ; Antimetabolites, Antineoplastic - administration & dosage ; Antineoplastic agents ; Biological and medical sciences ; Breast cancer ; Breast Neoplasms - drug therapy ; Breast Neoplasms - pathology ; Bridged-Ring Compounds - therapeutic use ; Cancer research ; Cancer therapies ; Chemotherapy ; Deoxycytidine - administration & dosage ; Deoxycytidine - analogs & derivatives ; Disease-Free Survival ; Drug Administration Schedule ; Female ; Humans ; Infusions, Intravenous ; Medical sciences ; Middle Aged ; Neoplasm Metastasis ; Palliative Care ; Pharmacology. Drug treatments ; Taxoids ; Treatment Failure</subject><ispartof>Breast cancer research and treatment, 2001-03, Vol.66 (1), p.83-87</ispartof><rights>2001 INIST-CNRS</rights><rights>Copyright Kluwer Academic Publishers Mar 2001</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c348t-4db95f92f1bc6f1466a8e5f2801f5654cc5904ea3fadbdc3f6fffcfc9b6be61d3</citedby><cites>FETCH-LOGICAL-c348t-4db95f92f1bc6f1466a8e5f2801f5654cc5904ea3fadbdc3f6fffcfc9b6be61d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=963741$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11368414$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>SMORENBURG, C. H</creatorcontrib><creatorcontrib>BONTENBAL, M</creatorcontrib><creatorcontrib>SEYNAEVE, C</creatorcontrib><creatorcontrib>VAN ZUYLEN, C</creatorcontrib><creatorcontrib>DE HEUS, G</creatorcontrib><creatorcontrib>VERWEIJ, J</creatorcontrib><creatorcontrib>DE WIT, R</creatorcontrib><title>Phase II study of weekly gemcitabine in patients with metastatic breast cancer relapsing or failing both an anthracycline and a taxane</title><title>Breast cancer research and treatment</title><addtitle>Breast Cancer Res Treat</addtitle><description>A phase II study was performed to investigate the efficacy and tolerability of gemcitabine as third-line chemotherapy for patients with metastatic breast cancer, previously treated with both an anthracycline- and taxane-containing regimen. Twenty-three patients were treated with gemcitabine 1200 mg/m2 in a 30-min infusion on day 1, 8 and 15 of a 28 day cycle. Seventy-four percent of the patients had visceral metastases. No complete or partial responses were observed. Six patients (26%) had stable disease with a median duration of 4.0 months. The median time to progression was 1.9 months and the median survival time was 7.8 months. Neutropenia grade 3 and 4 was observed in four patients (18%). Non-hematological toxicity grade 3 included nausea and vomiting in 14%, skin toxicity in 9% and elevation of transaminases in 23% of the patients. Gemcitabine is ineffective as third-line single agent therapy in patients failing anthracycline and taxane treatment for metastatic breast cancer.</description><subject>Adult</subject><subject>Aged</subject><subject>Antibiotics, Antineoplastic - therapeutic use</subject><subject>Antimetabolites, Antineoplastic - administration & dosage</subject><subject>Antineoplastic agents</subject><subject>Biological and medical sciences</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Breast Neoplasms - pathology</subject><subject>Bridged-Ring Compounds - therapeutic use</subject><subject>Cancer research</subject><subject>Cancer therapies</subject><subject>Chemotherapy</subject><subject>Deoxycytidine - administration & dosage</subject><subject>Deoxycytidine - analogs & derivatives</subject><subject>Disease-Free Survival</subject><subject>Drug Administration Schedule</subject><subject>Female</subject><subject>Humans</subject><subject>Infusions, Intravenous</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Neoplasm Metastasis</subject><subject>Palliative Care</subject><subject>Pharmacology. Drug treatments</subject><subject>Taxoids</subject><subject>Treatment Failure</subject><issn>0167-6806</issn><issn>1573-7217</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpVkEGLFDEQhYMo7rh69iZBz-2mOul0x9uwrDqwoAc9N5V0ZSdrT3pMMqzzB_zdZthBEQrqUXzvFTzGXoN4D6KVV-sPIEDo3kDbSyOesBV0vWz6FvqnbCVA940ehL5gL3K-F0KYXpjn7AJA6kGBWrHfX7eYiW82PJfDdOSL5w9EP-Yjv6OdCwVtiMRD5HssgWLJ_CGULd9RwVzqyXGbqEruMDpKPNGM-xziHV8S9xjmk7RLtWCsU7YJ3dHNp1CME0de8BdGesmeeZwzvTrvS_b9482368_N7ZdPm-v1beOkGkqjJms6b1oP1mkPSmscqPPtIMB3ulPOdUYoQulxspOTXnvvnXfGaksaJnnJ3j7m7tPy80C5jPfLIcX6cmyhVbrTBip09Qi5tOScyI_7FHaYjiOI8VT7uB7_q7063pxjD3ZH0z_-3HMF3p0BzA5nn2pbIf_ljJa9AvkHK9SMQw</recordid><startdate>200103</startdate><enddate>200103</enddate><creator>SMORENBURG, C. H</creator><creator>BONTENBAL, M</creator><creator>SEYNAEVE, C</creator><creator>VAN ZUYLEN, C</creator><creator>DE HEUS, G</creator><creator>VERWEIJ, J</creator><creator>DE WIT, R</creator><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9-</scope><scope>K9.</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope></search><sort><creationdate>200103</creationdate><title>Phase II study of weekly gemcitabine in patients with metastatic breast cancer relapsing or failing both an anthracycline and a taxane</title><author>SMORENBURG, C. H ; BONTENBAL, M ; SEYNAEVE, C ; VAN ZUYLEN, C ; DE HEUS, G ; VERWEIJ, J ; DE WIT, R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c348t-4db95f92f1bc6f1466a8e5f2801f5654cc5904ea3fadbdc3f6fffcfc9b6be61d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antibiotics, Antineoplastic - therapeutic use</topic><topic>Antimetabolites, Antineoplastic - administration & dosage</topic><topic>Antineoplastic agents</topic><topic>Biological and medical sciences</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Breast Neoplasms - pathology</topic><topic>Bridged-Ring Compounds - therapeutic use</topic><topic>Cancer research</topic><topic>Cancer therapies</topic><topic>Chemotherapy</topic><topic>Deoxycytidine - administration & dosage</topic><topic>Deoxycytidine - analogs & derivatives</topic><topic>Disease-Free Survival</topic><topic>Drug Administration Schedule</topic><topic>Female</topic><topic>Humans</topic><topic>Infusions, Intravenous</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Neoplasm Metastasis</topic><topic>Palliative Care</topic><topic>Pharmacology. Drug treatments</topic><topic>Taxoids</topic><topic>Treatment Failure</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>SMORENBURG, C. H</creatorcontrib><creatorcontrib>BONTENBAL, M</creatorcontrib><creatorcontrib>SEYNAEVE, C</creatorcontrib><creatorcontrib>VAN ZUYLEN, C</creatorcontrib><creatorcontrib>DE HEUS, G</creatorcontrib><creatorcontrib>VERWEIJ, J</creatorcontrib><creatorcontrib>DE WIT, R</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><jtitle>Breast cancer research and treatment</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>SMORENBURG, C. H</au><au>BONTENBAL, M</au><au>SEYNAEVE, C</au><au>VAN ZUYLEN, C</au><au>DE HEUS, G</au><au>VERWEIJ, J</au><au>DE WIT, R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Phase II study of weekly gemcitabine in patients with metastatic breast cancer relapsing or failing both an anthracycline and a taxane</atitle><jtitle>Breast cancer research and treatment</jtitle><addtitle>Breast Cancer Res Treat</addtitle><date>2001-03</date><risdate>2001</risdate><volume>66</volume><issue>1</issue><spage>83</spage><epage>87</epage><pages>83-87</pages><issn>0167-6806</issn><eissn>1573-7217</eissn><coden>BCTRD6</coden><abstract>A phase II study was performed to investigate the efficacy and tolerability of gemcitabine as third-line chemotherapy for patients with metastatic breast cancer, previously treated with both an anthracycline- and taxane-containing regimen. Twenty-three patients were treated with gemcitabine 1200 mg/m2 in a 30-min infusion on day 1, 8 and 15 of a 28 day cycle. Seventy-four percent of the patients had visceral metastases. No complete or partial responses were observed. Six patients (26%) had stable disease with a median duration of 4.0 months. The median time to progression was 1.9 months and the median survival time was 7.8 months. Neutropenia grade 3 and 4 was observed in four patients (18%). Non-hematological toxicity grade 3 included nausea and vomiting in 14%, skin toxicity in 9% and elevation of transaminases in 23% of the patients. Gemcitabine is ineffective as third-line single agent therapy in patients failing anthracycline and taxane treatment for metastatic breast cancer.</abstract><cop>Dordrecht</cop><pub>Springer</pub><pmid>11368414</pmid><doi>10.1023/A:1010679127390</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0167-6806 |
| ispartof | Breast cancer research and treatment, 2001-03, Vol.66 (1), p.83-87 |
| issn | 0167-6806 1573-7217 |
| language | eng |
| recordid | cdi_proquest_journals_212465691 |
| source | MEDLINE; SpringerLink Journals |
| subjects | Adult Aged Antibiotics, Antineoplastic - therapeutic use Antimetabolites, Antineoplastic - administration & dosage Antineoplastic agents Biological and medical sciences Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - pathology Bridged-Ring Compounds - therapeutic use Cancer research Cancer therapies Chemotherapy Deoxycytidine - administration & dosage Deoxycytidine - analogs & derivatives Disease-Free Survival Drug Administration Schedule Female Humans Infusions, Intravenous Medical sciences Middle Aged Neoplasm Metastasis Palliative Care Pharmacology. Drug treatments Taxoids Treatment Failure |
| title | Phase II study of weekly gemcitabine in patients with metastatic breast cancer relapsing or failing both an anthracycline and a taxane |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T03%3A43%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Phase%20II%20study%20of%20weekly%20gemcitabine%20in%20patients%20with%20metastatic%20breast%20cancer%20relapsing%20or%20failing%20both%20an%20anthracycline%20and%20a%20taxane&rft.jtitle=Breast%20cancer%20research%20and%20treatment&rft.au=SMORENBURG,%20C.%20H&rft.date=2001-03&rft.volume=66&rft.issue=1&rft.spage=83&rft.epage=87&rft.pages=83-87&rft.issn=0167-6806&rft.eissn=1573-7217&rft.coden=BCTRD6&rft_id=info:doi/10.1023/A:1010679127390&rft_dat=%3Cproquest_cross%3E390309381%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=212465691&rft_id=info:pmid/11368414&rfr_iscdi=true |